A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
WILMINGTON, DEL. (November 14, 2025) – In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology ...
Study in Molecular Therapy Oncology shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types In a major step forward for cancer care, researchers at ...
Image Caption: Mechanisms of resistance to chemoradiotherapy in osteosarcoma. In chemoradiotherapy resistant OS cells, altered expression of the drug transporter proteins, RFC and ABC family, reduces ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback